Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Peggy Rentsch"'
Publikováno v:
Frontiers in Aging Neuroscience, Vol 16 (2024)
BackgroundFinding successful therapies for individuals with Alzheimer's disease (AD) remains an ongoing challenge. One contributing factor is that the mouse models commonly used in preclinical research primarily mimic the familial form of AD, whereas
Externí odkaz:
https://doaj.org/article/f5b7429455d145d9bf833d182505766a
Publikováno v:
Frontiers in Aging Neuroscience, Vol 16 (2024)
IntroductionDeveloping effective treatment for Alzheimer’s disease (AD) remains a challenge. This can be partially attributed to the fact that the mouse models used in preclinical research largely replicate familial form of AD, while majority of hu
Externí odkaz:
https://doaj.org/article/d5cbefc7fc1b484984d988aab9cb424f
Publikováno v:
Frontiers in Molecular Neuroscience, Vol 16 (2024)
IntroductionAccurate modelling of molecular changes in Alzheimer’s disease (AD) dementia is crucial for understanding the mechanisms driving neuronal pathology and for developing treatments. Synaptic dysfunction has long been implicated as a mechan
Externí odkaz:
https://doaj.org/article/22a7a85554b64a09a9bae084bef47db7
Publikováno v:
BMC Neuroscience, Vol 20, Iss 1, Pp 1-12 (2019)
Abstract Background Accurately assessing promising therapeutic interventions for human diseases depends, in part, on the reproducibility of preclinical disease models. With the development of transgenic mice, the rapid adaptation of a 6-OHDA mouse mo
Externí odkaz:
https://doaj.org/article/b45f6d8c45aa4b3d953ab814d2430af8
Publikováno v:
Neurobiology of Disease, Vol 134, Iss , Pp - (2020)
L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment used in Parkinson's disease (PD), l-dopa. Here we investigate the effect of HU-308, a cannabinoid CB2 receptor agonist, on LIDs. Utilizing a mouse model of PD and
Externí odkaz:
https://doaj.org/article/98f2ea79755e443fa1e68e75369ec475
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0167211 (2017)
Parkinson's disease is a chronic neurodegenerative disease characterized by a significant loss of dopaminergic neurons within the substantia nigra pars compacta region and a subsequent loss of dopamine within the striatum. A promising avenue of resea
Externí odkaz:
https://doaj.org/article/c39c788f4458490c8e0008e705895b9e
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0124325 (2015)
Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by a significant loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc) and a subsequent loss of dopamine (DA) within the striatum. Despite advances
Externí odkaz:
https://doaj.org/article/c3abe54aca994c8d9c1cd2221bfde525
Publikováno v:
BMC Neuroscience
BMC Neuroscience, Vol 20, Iss 1, Pp 1-12 (2019)
BMC Neuroscience, Vol 20, Iss 1, Pp 1-12 (2019)
Background Accurately assessing promising therapeutic interventions for human diseases depends, in part, on the reproducibility of preclinical disease models. With the development of transgenic mice, the rapid adaptation of a 6-OHDA mouse model of Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202180bf983a3cd1991247601484770e
https://hdl.handle.net/10453/132556
https://hdl.handle.net/10453/132556
Publikováno v:
Neurobiology of Disease, Vol 134, Iss, Pp-(2020)
L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment used in Parkinson's disease (PD), l-dopa. Here we investigate the effect of HU-308, a cannabinoid CB2 receptor agonist, on LIDs. Utilizing a mouse model of PD and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f90ba9874e2504ff06dc44b1f68a848
https://doi.org/10.1016/j.nbd.2019.104646
https://doi.org/10.1016/j.nbd.2019.104646
Autor:
Peggy Rentsch, Kong M. Li, Bryce Vissel, Kathryn J. Laloli, Russell Pickford, Aimee Lowth, Sandy Stayte
Publikováno v:
Experimental Neurology. 323:113062
The excitatory neurotransmitter glutamate is essential in basal ganglia motor circuits and has long been thought to contribute to cell death and degeneration in Parkinson's disease (PD). While previous research has shown a significant role of NMDA an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbd3a481b48484885d0e2b10fa81be2b
https://doi.org/10.1016/j.expneurol.2019.113062
https://doi.org/10.1016/j.expneurol.2019.113062